Piramal Pharma Ltd
Ticker: PPLPHARMA
Decent
57/100
☆ Add to Watchlist
Investing Reference
Price
193.50
Market Cap
25574.49
Debt/Equity
0.5977
ROE %
1.137
PB
3.1474
Promoter %
34.856
Pledge %
0.000
1Y Rev Growth %
11.336
5Y Rev Growth %
NP Margin %
0.974
NP Margin 5Y Avg %
3.373
Trading Reference
1M Return %
-4.642
6M Return %
-13.042
1Y Return %
-16.422
% Away 52W High
59.121
% Away 52W Low
6.477
Daily Volume
2274935
Investment Verdict
Risky
Score 50/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 14/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
More Options
E
Emami Ltd
Emami Ltd shows potential in the FMCG sector with decent growth prospects, but faces challenges in profitability and execution risks.
View details
S
Star Health and Allied Insurance Company Ltd
Star Health and Allied Insurance Company Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
I
IRB Infrastructure Developers Ltd
IRB Infrastructure Developers Ltd shows potential in a growing sector, but faces challenges in execution and valuation.
View details
I
Inventurus Knowledge Solutions Ltd
The stock presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns. Caution is advised for potential investors.
View details
I
Inox Wind Ltd
Inox Wind Ltd faces several challenges, including inconsistent growth and market competition, making it a risky investment at this time.
View details
N
National Securities Depository Ltd
National Securities Depository Ltd shows decent fundamentals with stable growth prospects, but faces some execution risks and competition.
View details
E
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals shows potential for growth, but faces several challenges that could impact its performance.
View details
S
Shyam Metalics and Energy Ltd
Shyam Metalics and Energy Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
Z
ZF Commercial Vehicle Control Systems India Ltd
ZF Commercial Vehicle Control Systems India Ltd shows potential for growth in a transitioning sector, but faces challenges in profitability and valuation metrics.
View details
F
Firstsource Solutions Ltd
Firstsource Solutions Ltd shows potential with consistent growth but faces challenges in profitability and competitive pressures.
View details
E
EIH Ltd
EIH Ltd shows potential in a recovering sector but faces challenges in growth consistency and market competition.
View details
A
Anand Rathi Wealth Ltd
Anand Rathi Wealth Ltd shows potential for growth in a competitive sector, but faces challenges in profitability and valuation metrics.
View details
W
Wockhardt Ltd
Wockhardt Ltd presents several risks, particularly in growth consistency and balance sheet strength, making it a risky investment at this time.
View details
A
Aegis Logistics Ltd
Aegis Logistics Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
M
Manappuram Finance Ltd
Manappuram Finance Ltd shows potential for growth but is facing several challenges that could impact its performance.
View details
O
Ola Electric Mobility Ltd
Ola Electric Mobility Ltd shows potential in a growing sector but faces significant challenges in execution and profitability.
View details
Business Overview
Piramal Pharma Ltd is a leading player in the Indian pharmaceutical sector, dedicated to providing innovative healthcare solutions. Catering to both domestic and international markets, the company focuses on developing high-quality generic and specialty medicines. With a commitment to research and development, Piramal Pharma plays a crucial role in enhancing patient outcomes and addressing unmet medical needs. Its robust portfolio and strategic partnerships position it as a trusted name in the industry.
- Established leader in the Indian pharmaceutical market
- Focus on innovative healthcare solutions
- Strong commitment to research and development
- Diverse portfolio of generic and specialty medicines
- Strategic partnerships enhancing growth and reach
Investment Thesis
Piramal Pharma Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's solid fundamentals and strategic initiatives position it well for future growth.
- Strong backing from the Piramal Group enhances credibility and trust.
- Growing digital services segment offers a robust growth runway.
- Attractive valuation metrics compared to industry peers, providing upside potential.
- Focus on innovation and expansion aligns with market trends.
- Resilient business model with diversified revenue streams mitigates risks.
Opportunity vs Risk
Opportunities
- Strong growth in healthcare sector
- Expanding product portfolio
- Strategic partnerships and collaborations
- Rising demand for generics
Risks ⚠️
- Regulatory challenges in pharma
- Intense market competition
- Currency fluctuations impact profits
- Dependence on key products
Peer Perspective
Piramal Pharma Ltd trades at a discount to peers like Sun Pharma and Dr. Reddy's, primarily due to margin pressures. A sustained improvement in operational efficiency could trigger a rerating in its valuation.
📊 Stock Investment Checklist (100 Points)
Piramal Pharma Ltd • Updated: 2025-09-17 15:06:48
-
8BusinessHighPharmaceutical sector is growing with increasing demand for healthcare.
-
10GrowthHighRevenue growth has been inconsistent, with some fluctuations in profit margins.
-
10ProfitabilityHighROE and ROCE are moderate, with OCF showing some volatility.
-
9ValuationHighP/E and P/B ratios are higher than industry averages, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity ratios need improvement.
-
6GovernanceGoodPromoter holding is decent, but there are concerns about pledging.
-
8DriversHighStrong growth drivers exist, but execution risks are notable.
-
5TechnicalsGoodMarket sentiment is mixed with low liquidity.
Final Score & Verdict
Score 57 / 100
• Decent
Piramal Pharma Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 70/100